Rafferty Asset Management
FULC icon

Rafferty Asset Management’s Fulcrum Therapeutics FULC Stock Holding History

Rafferty Asset Management’s Portfolio FULC Stock Details FULC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-32,368
Closed -$116K – 1155
2024
Q3 		$116K Buy
+32,368
New +$240K ﹤0.01% 1125
2022
Q1 		– Sell
-12,971
Closed -$229K – 1257
2021
Q4 		$229K Buy
+12,971
New +$257K ﹤0.01% 1196

Other funds holding FULC

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Rafferty Asset Management's FULC Position: Q4 2024 in Review

Rafferty Asset Management sold out of Fulcrum Therapeutics (FULC) in Q4 2024, closing a stake of 32,368 shares — an estimated $116K sold.

Rafferty Asset Management first reported a position in FULC in Q4 2021 and held it in 2 quarters. The position peaked at $229K in Q4 2021. 119 funds tracked by Wall St. Rank hold FULC as of Q4 2024.

  • Rafferty Asset Management reported no remaining Fulcrum Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Rafferty Asset Management sold 32,368 Fulcrum Therapeutics shares in Q4 2024, an estimated $116K.
  • Rafferty Asset Management first reported a position in Fulcrum Therapeutics in Q4 2021 and held it in 2 quarters.
  • Rafferty Asset Management's Fulcrum Therapeutics position peaked at $229K in Q4 2021.
  • 119 funds tracked by Wall St. Rank held Fulcrum Therapeutics as of Q4 2024.

Based on Rafferty Asset Management's 13F filing for Q4 2024, filed 14 Feb 2025.